GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (STU:BIX) » Definitions » Net Income

BioInvent International AB (STU:BIX) Net Income : €-37.78 Mil (TTM As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is BioInvent International AB Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. BioInvent International AB's Net Income for the three months ended in Dec. 2024 was €-10.16 Mil. Its Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was €-37.78 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. BioInvent International AB's Earnings per Share (Diluted) for the three months ended in Dec. 2024 was €-0.15.


BioInvent International AB Net Income Historical Data

The historical data trend for BioInvent International AB's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB Net Income Chart

BioInvent International AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.50 -27.11 -3.87 -29.53 -37.33

BioInvent International AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.69 -6.89 -12.16 -8.57 -10.16

BioInvent International AB Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

BioInvent International AB's Net Income for the fiscal year that ended in Dec. 2024 is calculated as

Net Income(A: Dec. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-37.317+-0.012+0+0.00099999999999767
=-37.33

BioInvent International AB's Net Income for the quarter that ended in Dec. 2024 is calculated as

Net Income(Q: Dec. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-10.157+-0.004+0+0
=-10.16

Net Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-37.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioInvent International AB  (STU:BIX) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

BioInvent International AB's Earnings per Share (Diluted) (EPS) for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


BioInvent International AB Net Income Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


BioInvent International AB Business Description

Traded in Other Exchanges
Address
Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines